MEK1/2

[Cancer Letters] Researchers investigated five BRAFV600E melanoma cell lines derived from drug-naïve tumor specimens to assess cell death response to encorafenib, a recently FDA-approved BRAFV600E inhibitor.

[Nature Immunology] Scientists found that MEK1/2 inhibition induced stem cell–like memory T cells that have naive phenotype with self-renewability, enhanced multipotency and proliferative capacity.

[Scientific Reports] Lab-on-a-chip technology was used to investigate the effects of basic fibroblast growth factor, mitomycin C, MEK1/2 inhibitor and fetal calf serum on human dermal fibroblast cell migration.

[Journal of Biological Chemistry] Investigators showed that pharmacological inhibition of BRAF-V600E or ERK1/2 in melanoma cells increased PARK2 expression.

[Signal Transduction and Targeted Therapy] Scientists discovered that prolonged treatment of colon cancer cells with insulin-like growth factor 1 receptor (IGF-1R) inhibitors stimulated p70 KDa ribosomal protein S6 kinase 1 (p70S6K1) activation, a well-known kinase signaling for cell survival. They also found that p70S6K1 activation by IGF-1R inhibition was independent of K-Ras and PIK3CA mutations that frequently occur in colon cancer.

[Cell Reports] Scientists showed that expression of the TPR-NTRK1 fusion kinase in immortalized mouse pancreatic ductal epithelial or mouse lung epithelial cells was sufficient to promote rapidly growing tumors in mice.